Comparative Performance of Breast Cancer Human Epidermal Growth Factor Receptor 2 Fluorescence In Situ Hybridization and Brightfield In Situ Hybridization on College of American Pathologists Proficiency Tests

被引:3
作者
Geiersbach, Katherine B. [1 ]
Bridge, Julia A. [2 ]
Dolan, Michelle [3 ]
Jennings, Lawrence J. [4 ]
Persons, Diane L. [5 ]
Souers, Rhona J. [6 ]
Tsuchiya, Karen D. [8 ]
Vasalos, Patricia H. [7 ]
Moncur, Joel T. [9 ]
机构
[1] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[2] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA
[3] Univ Minnesota, Med Sch, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
[4] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pathol, Chicago, IL 60611 USA
[5] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA
[6] Coll Amer Pathologists, Dept Biostat, Northfield, IL USA
[7] Coll Amer Pathologists, Dept Proficiency Testing, Northfield, IL USA
[8] Seattle Childrens Hosp, Dept Labs, Seattle, WA USA
[9] Walter Reed Natl Mil Med Ctr, Dept Pathol, 8901 Wisconsin Ave,Bldg 9,Basement,Room 0849, Bethesda, MD 20889 USA
关键词
HER-2/NEU GENE AMPLIFICATION; HER2; DUAL-COLOR; GUIDELINE RECOMMENDATIONS; CLINICAL ONCOLOGY/COLLEGE; ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; FISH; TRASTUZUMAB; SOCIETY; CARCINOMA;
D O I
10.5858/arpa.2017-0457-CP
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-Fluorescence in situ hybridization (FISH) and brightfield in situ hybridization (ISH) are 2 clinically approved laboratory methods for detecting ERBB2 (HER2) amplification in breast cancer. Objective.-To compare the performance of FISH and brightfield ISH on proficiency testing administered by the College of American Pathologists Laboratory Accreditation Program. Design.-Retrospective review was performed on 70 tissue core samples in 7 separate proficiency testing surveys conducted between 2009 and 2013. Results.-The samples included 13 consensus-amplified tissue cores, 53 consensus-nonamplified cores, and 4 cores that did not reach consensus for FISH and/or brightfield ISH. There were 2552 individual responses for FISH and 1871 individual responses for brightfield ISH. Consensus response rates were comparable for FISH (2474 of 2524; 98.0%) and brightfield ISH (2135 of 2189; 97.5%). The FISH analysis yielded an average HER2 copy number per cell that was significantly higher (by 2.86; P = .02) compared with brightfield ISH for amplified cores. For nonamplified cores, FISH yielded slightly, but not significantly, higher (by 0.17; P = .10) HER2 copy numbers per cell. There was no significant difference in the average HER2 to control ratio for either consensusamplified or consensus-nonamplified cores. Participants reported "unable to analyze" more frequently for brightfield ISH (244 of 2453; 9.9%) than they did for FISH (160 of 2684; 6.0%). Conclusions.-Our study indicates a high concordance rate in proficiency testing surveys, with some significant differences noted in the technical performance of these assays. In borderline cases, updated American Society of Clinical Oncology/College of American Pathologists cutoff thresholds that place greater emphasis on HER2 copy number per cell could accentuate those differences between FISH and brightfield ISH.
引用
收藏
页码:1254 / 1259
页数:6
相关论文
共 43 条
  • [1] A UK NEQAS ISH Multicenter Ring Study Using the Ventana HER2 Dual-Color ISH Assay
    Bartlett, J. M. S.
    Campbell, Fiona M.
    Ibrahim, Merdol
    O'Grady, Anthony
    Kay, Elaine
    Faulkes, Catherine
    Collins, Nadine
    Starczynski, Jane
    Morgan, John M.
    Jasani, Bharat
    Miller, Keith
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2011, 135 (01) : 157 - 162
  • [2] Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization
    Bethune, Gillian C.
    van Zanten, Daniel Veldhuijzen
    MacIntosh, Rebecca F.
    Rayson, Daniel
    Younis, Tallal
    Thompson, Kara
    Barnes, Penny J.
    [J]. HISTOPATHOLOGY, 2015, 67 (06) : 880 - 887
  • [3] Real Time RT-PCR Approach for the Evaluation of ERBB2 Overexpression in Breast Cancer Archival Samples: A Comparative Study With FISH, SISH, and Immunohistochemistry
    Capizzi, Elisa
    Gruppioni, Elisa
    Grigioni, Antonia D'Errico
    Gabusi, Elena
    Grassigli, Alberto
    Grigioni, Walter Franco
    Fiorentino, Michelangelo
    [J]. DIAGNOSTIC MOLECULAR PATHOLOGY, 2008, 17 (04) : 220 - 226
  • [4] Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists
    Carbone, Antonino
    Botti, Gerardo
    Gloghini, Annunziata
    Simone, Gianni
    Truini, Mauro
    Curcio, Maria Pia
    Gasparini, Patrizia
    Mangia, Anita
    Perin, Tiziana
    Saivi, Sandra
    Testi, Adele
    Verderio, Paolo
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2008, 10 (06) : 527 - 536
  • [5] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
    Cobleigh, MA
    Vogel, CL
    Tripathy, D
    Robert, NJ
    Scholl, S
    Fehrenbacher, L
    Wolter, JM
    Paton, V
    Shak, S
    Lieberman, G
    Slamon, DJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2639 - 2648
  • [6] Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer
    Di Palma, S.
    Collins, N.
    Faulkes, C.
    Ping, B.
    Ferns, G.
    Haagsma, B.
    Layer, G.
    Kissin, M. W.
    Cook, M. G.
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (09) : 1067 - 1068
  • [7] HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline
    Fan, Yao-Shan
    Casas, Carmen E.
    Peng, Jinghong
    Watkins, Melanie
    Fan, Lynn
    Chapman, Jennifer
    Ikpatt, Offiong Francis
    Gomez, Carmen
    Zhao, Wei
    Reis, Isildinha M.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (03) : 457 - 462
  • [8] Bright-Field HER2 Dual In Situ Hybridization (DISH) Assay vs Fluorescence In Situ Hybridization (FISH) Focused Study of Immunohistochemical 2+Cases
    Gao, Faye F.
    Dabbs, David J.
    Cooper, Kristine L.
    Bhargava, Rohit
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 141 (01) : 102 - 110
  • [9] Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens
    Garcia-Caballero, Tomas
    Grabau, Dorthe
    Green, Andrew R.
    Gregory, John
    Schad, Arno
    Kohlwes, Elke
    Ellis, Ian O.
    Watts, Sarah
    Mollerup, Jens
    [J]. HISTOPATHOLOGY, 2010, 56 (04) : 472 - 480
  • [10] Performance of Chromogenic In Situ Hybridization on Testing HER2 Status in Breast Carcinomas With Chromosome 17 Polysomy and Equivocal (2+) HercepTest Results
    Gong, Yun
    Sweet, William
    Duh, Yi-Jing
    Greenfield, Larry
    Tarco, Emily
    Trivedi, Smita
    Symmans, W. Fraser
    Isola, Jorma
    Sneige, Nour
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 132 (02) : 228 - 236